A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis (MASH) and F2/F3 Fibrosis (FASCINATE-3)

A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression without the worsening of steatohepatitis.

开始日期2024-12-01

申办/合作机构

Sagimet Biosciences, Inc.

CTR20240230 / Recruiting临床3期

评价ASC40（地尼法司他）片治疗中、重度寻常性痤疮患者的长期安全性的开放、多中心、III期延伸临床研究

观察长期使用ASC40（地尼法司他）片治疗中、重度寻常性痤疮患者的安全性

开始日期2024-04-18

申办/合作机构

歌礼生物科技（杭州）有限公司

NCT06248008 / Recruiting临床3期

An Open, Multicenter, Phase III Extension Clinical Trial to Evaluate the Long-term Safety of ASC40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne Vulgaris

This is a multicenter, open-label study designed to determine the long-term safety of ASC40 (Denifanstat) tablets in patients with moderate to severe acne vulgaris enrolled in the ASC40-303 Phase III study. All subjects are eligible for study eligibility screening after enrollment in ASC40-303 Phase III study, and all eligible subjects with moderate to severe acne vulgaris will receive ASC40 (Denifanstat) tablets after signing informed consent. The investigational drug will be administered orally once daily (QD) for up to 40 weeks. There will be a total of 7 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc.

开始日期2024-04-18

申办/合作机构

歌礼药业（浙江）有限公司

100 项与地尼法司他相关的临床结果

登录后查看更多信息

100 项与地尼法司他相关的转化医学

登录后查看更多信息

100 项与地尼法司他相关的专利（医药）

登录后查看更多信息

项与地尼法司他相关的文献（医药）

2024-12-01·INTERNATIONAL IMMUNOPHARMACOLOGY

FASN contributes to the pathogenesis of lupus by promoting TLR-mediated activation of macrophages and dendritic cells

Article

作者: Ning, Zhaochen ; Hu, Yuxin ; Xiao, Yucai ; Ma, Qun ; Xiong, Huabao ; Dong, Guanjun ; Yu, Lu ; Liu, Jiakun ; Li, Haochen ; Zhang, Xin ; Wang, Lin ; Zhang, Lili ; Yang, Yonghong ; Gao, Yangzhe ; Dai, Jun

Hyper-activations of monocytes/macrophages and dendritic cells (DCs) contribute to the pathogenesis of various autoimmune diseases, such as systemic lupus erythematosus (SLE). Fatty acid synthase (FASN) is essential for the de novo synthesis of long-chain fatty acids, which play a key role in controlling the activation, differentiation, and function of immune cells. However, the role of FASN in regulating the activations of monocytes/macrophages and DCs has not been studied. In this study, we investigated the involvement of the FASN in modulating the activations of macrophages and DCs, as well as the pathogenesis of SLE. Importantly, we observed a significant upregulation of FASN expression in monocytes and DCs from patients with SLE. This increase is strongly correlated with disease severity and activation status of the immune cells. Furthermore, overexpression of FASN significantly boosts the TLR4/7/9-mediated activation of macrophages and DCs, while knockdown of FASN markedly inhibits this activation. Notably, knockdown of FASN alleviates TLR7 agonist imiquimod (IMQ)-induced lupus in mice and the activation of macrophages and DCs. It makes more sense that pharmaceutical targeting of FASN by using TVB-2640 significantly alleviates IMQ-induced lupus in mice and the activation of macrophages and DCs, as well as in spontaneous lupus MRL/lpr mice. Thus, FASN contributes to the TLRs-mediated activation of macrophages and DCs, as well as the pathogenesis of SLE. More importantly, FASN inhibitor TVB-2640 is expected to be an effective drug in the treatment of SLE.

2024-12-01·Lancet Gastroenterology & Hepatology

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

Article

作者: Loomba, Rohit ; O'Farrell, Marie ; Bruno Martins, Eduardo ; Lawitz, Eric ; McCulloch, William ; Tsai, Wen-Wei ; Harrison, Stephen A ; Cobiella, Jose ; Grimmer, Katharine ; Rudraraju, Madhavi ; Bedossa, Pierre ; Kemble, George

BACKGROUND:

Denifanstat, an oral fatty acid synthase (FASN) inhibitor, blocks de-novo lipogenesis, a key pathway driving progressive lipotoxicity, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to examine the safety and efficacy of denifanstat for improving liver histology in individuals with MASH and moderate to advanced fibrosis.

METHODS:

This multicentre, double-blind, randomised, placebo-controlled, phase 2b trial was conducted at 100 clinical sites in the USA, Canada, and Poland. After a screening period of up to 90 days, participants aged 18 years and older with biopsy-confirmed MASH and stage F2 or F3 fibrosis were randomly assigned (2:1) to receive either 50 mg oral denifanstat or placebo once per day for 52 weeks. Participants were dynamically allocated to treatment groups via a centrally administered interactive web-based response system and stratified by type 2 diabetes, region, and fibrosis stage. Investigators, patients, and the sponsor were masked to group allocation until database lock. The primary efficacy endpoints were a 2-point or greater improvement in non-alcoholic fatty liver disease activity score (NAS) without a worsening of fibrosis or MASH resolution with a 2-point or greater improvement in NAS without a worsening of fibrosis at week 52, assessed by intention to treat. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04906421, and is closed for enrolment.

FINDINGS:

Of the 1087 individuals screened between June 2, 2021, and June 28, 2022, 168 eligible participants were randomly assigned to receive a dose of 50 mg denifanstat once per day (n=112) or placebo (n=56). All 168 participants (100 female, 68 male) received at least one dose of study treatment. In the ITT population, 42 (38%) of 112 participants in the denifanstat group had a 2-point or greater improvement in NAS without a worsening of fibrosis versus nine (16%) of 56 participants in the placebo group (common risk difference 21·0%, 95% CI 8·1-33·9; p=0·0035). 29 (26%) of 112 participants in the denifanstat group showed MASH resolution with a 2-point or greater improvement in NAS without a worsening of fibrosis compared with six (11%) of 56 participants in the placebo group (common risk difference 13·0%, 0·7-25·3; p=0·0173). The most common treatment-emergent adverse events were COVID-19 (19 [17%] of 112 in the denifanstat group vs six [11%] of 56) in the placebo group, dry eye symptoms (ten [9%] of 112 vs eight [14%] of 56), and alopecia (21 [19%] of 112 vs two [4%] of 56). All adverse events considered to be related to the study drug were of grade 1 or grade 2. None of the serious adverse events (13 [12%] of 112 participants in the denifanstat group vs three [5%] of 56 in the placebo group) were considered drug-related.

INTERPRETATION:

Treatment with denifanstat resulted in statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis. The results of this phase 2b trial support the advancement of denifanstat to phase 3 development.

FUNDING:

Sagimet Biosciences.

2024-09-06·JOURNAL OF PROTEOME RESEARCH

FAS Inhibited Proteomics and Phosphoproteomics Profiling of Colorectal Cancer Spheroids Shows Activation of Ferroptotic Death Mechanism

Article

作者: Fries, Brian D. ; Hummon, Amanda B. ; Hummon, Amanda B ; Fries, Brian D

Colorectal cancer (CRC) is projected to become the third most diagnosed and third most fatal cancer in the United States by 2024, with early onset CRC on the rise. Research is constantly underway to discover novel therapeutics for the treatment of various cancers to improve patient outcomes and survival. Fatty acid synthase (FAS) has become a druggable target of interest for the treatment of many different cancers. One such inhibitor, TVB-2640, has gained popularity for its high specificity for FAS and has entered a phase 1 clinical trial for the treatment of solid tumors. However, the distinct molecular differences that occur upon inhibition of FAS have yet to be understood. Here, we conduct proteomics and phosphoproteomics analyses on HCT 116 and HT-29 CRC spheroids inhibited with either a generation 1 (cerulenin) or generation 2 (TVB-2640) FAS inhibitor. Proteins involved in lipid metabolism and cellular respiration were altered in abundance. It was also observed that proteins involved in ferroptosis─an iron mediated form of cell death─were altered. These results show that HT-29 spheroids exposed to cerulenin or TVB-2640 are undergoing a ferroptotic death mechanism. The data were deposited to the ProteomeXchange Consortium via the PRIDE repository with the identifier PXD050987.

165

项与地尼法司他相关的新闻（医药）

2024-11-12

·歌礼

歌礼完成ASC40（地尼法司他）每日一次口服片治疗痤疮III期临床试验患者入组

-III期试验共入组了480例中、重度痤疮患者 -顶线结果预计将于2025年第2季度公布中国杭州，2024年11月12日--歌礼制药有限公司（香港联交所代码：1672，“歌礼”）今日宣布已完成ASC40（地尼法司他）每日一次口服片治疗中、重度痤疮III期临床试验的480例患者入组。首例患者已于2024年1月24日入组。这项III期临床试验是一项在中国开展的随机、双盲、安慰剂对照、多中心的临床试验，旨在评估ASC40每日一次口服片治疗中、重度寻常性痤疮的安全性和疗效。480例中、重度寻常性痤疮患者按照1:1的比例被随机分至一个活性药物组和一个安慰剂对照组，接受每日一次50毫克ASC40口服片或匹配的安慰剂治疗，为期12周。顶线结果预计将于2025年第2季度公布。试验主要疗效终点为：第12周时，治疗成功的患者比例、总皮损计数较基线的百分比变化、以及炎性皮损计数较基线的百分比变化。治疗成功的定义为：研究者总体评估（Investigator's Global Assessment，IGA）评分较基线下降至少2分，且IGA分级为光洁（0分）或几乎光洁（1分）。 2023年5月2日，歌礼宣布ASC40每日一次口服片治疗寻常性痤疮的II期临床试验达到主要及关键次要终点，表现出了显著的疗效（包括与安慰剂组（5.1%）相比，19.4%患者于第12周治疗成功）和良好的安全性（链接）。 ASC40是一款同类首创、每日一次口服、选择性小分子脂肪酸合成酶（FASN）抑制剂。ASC40治疗痤疮的机制是：（1）通过抑制人皮脂细胞的脂肪酸从头合成（DNL），直接抑制面部皮脂生成；和（2）通过减少细胞因子分泌和Th17分化来抑制炎症。歌礼已从Sagimet Biosciences Inc.（纳斯达克股票代码：SGMT）获得ASC40的大中华区独家授权。吴劲梓博士歌礼创始人、董事会主席兼首席执行官作为一款拥有治疗痤疮全新机制的同类首创、每日一次口服候选药物，ASC40在II期研究中显示出了积极的疗效和良好的安全性。我们期待在2025年第2季度公布ASC40（地尼法司他）III期试验顶线结果。关于歌礼制药有限公司歌礼是一家在香港证券交易所上市（1672.HK）的创新研发驱动型生物科技公司，涵盖了从新药研发至GMP生产的完整价值链。歌礼的管理团队具备深厚的专业知识及优秀的过往成就，在团队的带领下，歌礼快速推进药物管线开发，聚焦两大临床需求尚未满足的医疗领域：代谢性疾病和病毒性疾病，并以全球化的视野进行布局。歌礼的研发管线拥有多款在研药物。欲了解更多信息，敬请登录网站：www.ascletis.com。

临床3期ASCO会议临床结果临床2期

2024-11-12

·PRNewswire

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024. This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40 once-daily oral tablet for the treatment of moderate to severe acne vulgaris. 480 patients with moderate to severe acne vulgaris were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg ASC40 oral tablet once daily or matching placebo for 12 weeks. Topline results are expected in the second quarter 2025. The primary efficacy endpoints are the proportion of patients achieving treatment success at week 12, the percentage change from baseline in total lesion count at week 12, and the percentage change from baseline in inflammatory lesion count at week 12. Treatment success is defined as at least a 2-point reduction in Investigator's Global Assessment (IGA) score from baseline and a score of clear (0) or almost clear (1). On May 2, 2023, Ascletis announced that the Phase II clinical trial for ASC40 once-daily oral tablet for the treatment of acne vulgaris met the primary and key secondary endpoints, demonstrating superior efficacy including 19.4% patients achieving treatment success at week 12 versus placebo (5.1%) and a good safety profile (Link). ASC40 is a first-in-class, once-daily oral, selective small molecule inhibitor of fatty acid synthase (FASN). Mechanisms of ASC40 for treatment of acne are (1) direct inhibition of facial sebum production through inhibition of de novo lipogenesis (DNL) in human sebocytes, and (2) inhibition of inflammation through decreasing cytokine secretion and Th17 differentiation. ASC40 is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "As a first-in-class once-daily oral drug candidate with novel mechanism for acne treatment, ASC40 has shown positive efficacy and a good safety profile in the Phase II study. We look forward to announcing topline results of the ASC40 (denifanstat) Phase III trial in the second quarter 2025." said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis has rapidly advanced its pipeline, focusing on two therapeutic areas with unmet medical needs from a global perspective: metabolic diseases and viral diseases. Ascletis has multiple clinical stage drug candidates in its R&D pipeline. For more information, please visit . Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) [email protected] [email protected] SOURCE Ascletis Pharma Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床3期临床结果

2024-11-08

·PRNewswire

HistoIndex to Present Latest Findings on AI-based Analysis using Stain-free Digital Pathology with 12 Accepted Abstracts at AASLD The Liver Meeting® 2024

SINGAPORE, Nov. 8, 2024 /PRNewswire/ -- HistoIndex, a pioneering leader in artificial intelligence (AI) and stain-free digital pathology, will present its latest research findings and advancements in AI-based analysis at the 75th The Liver Meeting® (TLM) 2024, hosted by the American Association for the Study of Liver Diseases (AASLD). The conference, which brings together leading scientists, clinicians, and industry experts in hepatology, will be held from November 15th to 19th, in San Diego, California. HistoIndex's team, including the KOLs involved in the studies, will be sharing insights into the company's innovative approach to assess regression and progression of liver fibrosis, including groundbreaking AI-enabled methodology that enhance the detection, quantification, and assessment of various liver conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH) and fibrosis. With the incidence of liver diseases rising globally, these presentations are timely in showcasing how HistoIndex's stain-free digital pathology solutions and AI technology address current challenges by providing highly accurate, reproducible, and interpretable data from liver biopsies. As a leader in AI-based analysis using stain-free digital pathology, we are honored to have extensive representation at TLM 2024, showcasing twelve abstracts from phase 2b and phase 3 clinical trials that span four distinct mechanisms of action (MOA) in MASH. Commenting on the significance of the accepted abstracts, Dr. Dean Tai, Chief Scientific Officer at HistoIndex stated, "These findings from the four distinct MOA phase 2b/3 MASH trials, along with diverse studies highlighting the utility of our technology in cirrhotic MASH, differentiating pediatric and adult MASH, predicting clinical outcomes, and understanding hepatocellular carcinoma recurrence in chronic hepatitis B patients, underscore the transformative role of AI in advancing liver disease diagnosis, prognosis and personalized treatment. We are excited to share these advancements and their impact on clinical trials leading to routine clinical care." Key Highlights from HistoIndex at TLM 2024 The HistoIndex team will be involved in multiple oral and poster sessions, highlighting its commitment to advancing liver research and supporting the global hepatology community: Oral Presentation | Sunday, November 17th, 2.45pm - 3pm Title: AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis - results of the FASCINATE-2 study Presenter: Dr. Mary Rinella Publication Number: 170 Poster Presentations Poster Session I | Friday, November 15th, 1:00 PM – 2:00 PM Title: Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease Presenter: Dr Zhengxin Li Publication Number: 1561 Title: The role of steatosis and fibrosis parameters in predicting hepatocellular carcinoma recurrence in chronic hepatitis B patients Presenter: Dr Ke Yin Publication Number: 1275 Poster Session II | Saturday, November 16th, 1:00 PM – 2:00 PM Title: Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis. Presenter: Dr Naim Alkhouri Publication Number: TBC Title: Evaluating impact of weight changes on histological patterns of liver fibrosis in MASH: implications for spatial interrogation Presenter: Dr Kutbuddin Akbary Publication Number: 2114 Title: Evaluation of the consistency and heterogeneity of adjacent sections in fibrosis assessment using AI-based qFibrosis in virtual liver needle biopsies Presenter: Dr Yayun Ren Publication Number: 2047 Title: Independent validation of second harmonic generation/two photon excitation imaging and artificial intelligence-based SNOF index for metabolic dysfunction associated steatohepatitis cirrhosis assessment Presenter: Dr Kutbuddin Akbary Publication Number: 2065 Title: Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease Presenter: Dr Jonathan Fallowfield Publication Number: 2080 Poster Session III | Sunday, November 17th, 1:00 PM – 2:00 PM Title: Fibrosis regression after Tirzepatide treatment of non-cirrhotic MASH for 52 weeks occurs in a zone-dependent manner Presenter: Dr Arun Sanyal Publication Number: 3202 Title: Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH Presenter: Dr Jörn Schattenberg Publication Number: 3184 Poster Session: Late Breaking Posters | Monday, November 18th: 8:00 AM – 5:00 PM Title: AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with Efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study Presenter: Dr Mazen Noureddin Publication Number: 5047 Title: Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study Presenter: Dr Mazen Noureddin Publication Number: 5021 Breakfast Meeting: Bridging Clinical Research and Clinical Care In addition to the scientific sessions, HistoIndex will be hosting a breakfast meeting on November 15th, offering a unique opportunity for clinicians, researchers, and industry partners to interact with the HistoIndex team and KOLs on the transformative potential of AI-based analysis using stain-free digital pathology in current MASH clinical trials and its role in the routine clinical care of MASH patients post drug approvals. If you are keen, please register here today at . Visit HistoIndex at Booth #1225 All attendees of TLM 2024 are invited to visit the HistoIndex exhibition booth #1225 and experience the company's Second Harmonic Generation (SHG) technology and AI-enabled analytics with hands-on interactive demonstrations. The exhibition booth will be staffed by knowledgeable company representatives eager to engage with attendees and discuss potential partnerships. For more information about HistoIndex's participation in TLM 2024, please visit . --- About HistoIndex Founded in 2010, HistoIndex pioneers in stain-free, fully automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. By combining cutting-edge biophotonic technology with AI-based analysis, HistoIndex provides innovative tools to improve the assessment of fibrosis changes and drug efficacy. The Company's breakthrough digital pathology solutions are accelerating research, expediting pharmaceutical drug development, and transforming medical standards. SOURCE HistoIndex WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期

100 项与地尼法司他相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
纤维化	临床3期	-	Sagimet Biosciences, Inc.	2024-12-01
非酒精性脂肪肝	临床3期	-	Sagimet Biosciences, Inc.	2024-12-01
非酒精性脂肪性肝炎	临床3期	-	Sagimet Biosciences, Inc.	2024-12-01
寻常痤疮	临床3期	中国	歌礼生物科技（杭州）有限公司	2024-01-23
复发性胶质母细胞瘤	临床3期	中国	歌礼药业（浙江）有限公司	2022-01-21
胶质母细胞瘤	临床3期	中国	歌礼生物科技（杭州）有限公司	2021-12-17
KRAS突变非小细胞肺癌	临床2期	美国	Sagimet Biosciences, Inc.	2019-09-11
代谢综合征	临床2期	美国	Sagimet Biosciences, Inc.	2017-02-01
转移性去势抵抗性前列腺癌	临床1期	美国	Sagimet Biosciences, Inc.	2023-11-20
肝损伤	临床1期	美国	Sagimet Biosciences, Inc.	2023-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04906421 (FASCINATE-2, Biospace) 人工标引	临床2期	非酒精性脂肪性肝炎	168	Denifanstat	顧簾襯壓襯鹹蓋積蓋簾(鬱簾顧鏇淵蓋網齋構鹽) = 襯獵鑰鏇範簾淵製醖餘製膚衊艱鏇壓構築構壓 (製構醖選壓壓廠壓壓顧 ) 更多	积极	2024-10-11
				Placebo	顧簾襯壓襯鹹蓋積蓋簾(鬱簾顧鏇淵蓋網齋構鹽) = 艱簾窪築選顧鹹觸鑰醖製膚衊艱鏇壓構築構壓 (製構醖選壓壓廠壓壓顧 ) 更多
NCT04906421 (FASCINATE-2, EASL2024) 人工标引	临床2期	纤维化	168	Denifanstat 50 mg	鑰鏇製鹹膚窪窪窪顧鹹(襯鏇衊壓選蓋襯鬱網構) = 簾鹽襯鬱廠簾顧鬱網夢鑰鹽衊憲廠壓獵遞襯網 (餘築積鑰鑰觸艱簾窪廠 ) 更多	积极	2024-06-01
				Placebo	鑰鏇製鹹膚窪窪窪顧鹹(襯鏇衊壓選蓋襯鬱網構) = 窪夢簾齋選繭壓範醖蓋鑰鹽衊憲廠壓獵遞襯網 (餘築積鑰鑰觸艱簾窪廠 ) 更多
NCT05104125 (AAD2024) 人工标引	临床2期	寻常痤疮	180	ASC40 25mg	餘淵窪觸淵艱壓觸願範(蓋觸鬱膚範築繭鹽獵選) = 遞鬱膚壓鑰淵廠選鑰遞積願壓選獵鹹襯夢簾構 (醖窪膚鑰膚獵構餘衊糧 ) 更多	积极	2024-03-10
				ASC40 50mg	餘淵窪觸淵艱壓觸願範(蓋觸鬱膚範築繭鹽獵選) = 憲衊鹽壓鏇膚廠醖膚構積願壓選獵鹹襯夢簾構 (醖窪膚鑰膚獵構餘衊糧 ) 更多
NCT04906421 (FASCINATE-2, Biospace) 人工标引	临床2期	非酒精性脂肪性肝炎	168	Denifanstat	範製積鬱窪積壓醖糧網(衊網構鑰積觸鹹壓鑰廠) = 築壓糧廠窪鏇窪壓糧壓顧襯糧齋鹹鏇觸鏇願醖 (壓願構艱選壓觸範襯積 ) 更多	积极	2024-01-22
				Placebo	範製積鬱窪積壓醖糧網(衊網構鑰積觸鹹壓鑰廠) = 簾繭鏇簾選餘選積醖構顧襯糧齋鹹鏇觸鏇願醖 (壓願構艱選壓觸範襯積 ) 更多
NCT03032484 (CTgov)	临床2期	星形细胞瘤	25	TVB-2640+Bevacizumab	餘壓繭鏇膚齋鬱壓憲鏇(夢積壓膚積獵繭觸餘襯) = 糧淵願積憲範鹹製鏇遞廠憲鬱簾糧鹽齋鏇獵築 (餘衊範醖淵顧衊積衊淵, 醖淵積艱齋廠鹽醖衊構 ~ 蓋憲製構餘淵積憲製淵) 更多	-	2023-06-15
NCT02948569 (CTgov)	临床1/2期	代谢综合征	12	3-V Bioscience-2640	膚遞鹹齋鬱餘廠齋鹹壓(艱衊構鏇鑰網窪糧選襯) = 築蓋選簾築築鹹鹽蓋築鑰襯憲製夢鏇積顧夢製 (構窪壓醖蓋衊繭積醖膚, 蓋選淵鹹構糧簾糧膚簾 ~ 糧顧衊襯廠憲糧選膚襯) 更多	-	2023-04-20
NASH_TAG2023	N/A	非酒精性脂肪性肝炎	-	Denifanstat 50mg	廠蓋範膚範網積壓遞廠(憲顧窪鏇製築蓋鏇廠鑰) = 鹹壓鑰鹽膚鹹鑰窪膚憲鹹遞積壓範艱餘構壓鏇 (淵糧醖願鏇蓋襯構網鹽 ) 更多	-	2023-01-05
				Placebo	廠蓋範膚範網積壓遞廠(憲顧窪鏇製築蓋鏇廠鑰) = 製簾觸襯顧製醖繭齋糧鹹遞積壓範艱餘構壓鏇 (淵糧醖願鏇蓋襯構網鹽 )
NCT04906421 (FASCINATE-2, NEWS) 人工标引	临床2期	非酒精性脂肪性肝炎	52	Denifanstat	夢鏇製窪襯壓夢膚觸夢(選選鹽獵網壓襯壓製憲) = 膚簾膚選淵繭襯醖鑰獵壓廠網願鏇襯製憲選鹹 (襯獵廠餘憲鑰鑰蓋顧鹹 ) 更多	积极	2022-11-04
				Placebo	夢鏇製窪襯壓夢膚觸夢(選選鹽獵網壓襯壓製憲) = 壓製積繭鏇鹹獵選壓鬱壓廠網願鏇襯製憲選鹹 (襯獵廠餘憲鑰鑰蓋顧鹹 ) 更多
NCT03032484 (Corporate Publications) 人工标引	临床2期	星形细胞瘤	180	Bevacizumab+Denifanstat	願廠網餘願鬱鹹網膚簾(齋廠齋醖網襯繭蓋廠鑰) = 製壓鬱網鹽簾餘築顧鹹鏇鏇積範積顧築遞淵齋 (願觸繭餘鏇鏇蓋鬱範觸 ) 更多	-	2022-08-22